Citius Oncology gets Nasdaq extension to April 19, 2027 to regain $1.00 bid price
Citius Oncology received a Nasdaq notice on October 19, 2026 granting it until April 19, 2027 to evidence compliance with the $1.00 per share minimum bid price rule for continued Nasdaq Capital Market listing. The company's stock will keep trading under the symbol CTOR for now, but if it does not regain compliance by that date, Nasdaq will notify it that the stock is subject to delisting, and the company may appeal to a hearings panel.
Key points
- Nasdaq extension runs through April 19, 2027 for compliance with the $1.00 per share bid price requirement.
- Compliance requires a closing bid price of $1.00 or more for at least ten consecutive business days before April 19, 2027.
- The company says it is evaluating options for regaining compliance and cannot assure it will do so.
- The extension has no immediate effect on the CTOR listing on The Nasdaq Capital Market.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.